Mark Ratner. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Angiogenesis Inhibitors/adverse effectsAngiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal, Humanized/adverse effectsAntibodies, Monoclonal, Humanized/therapeutic useBevacizumabBreast Neoplasms/blood supplyBreast Neoplasms/drug therapyDrug ApprovalDrug Industry/economicsDrug Industry/legislation & jurisprudenceFemaleHumansUnited StatesUnited States Food and Drug Administration/legislation & jurisprudence
Substances： See more » Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumab
Year: 2011 PMID： 21822226 DOI： 10.1038/nbt0811-676c
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908